SC7: Using IP Landscape Studies to Improve Your Confidence While Navigating a Crowded IP and Technology Space
Monday, September 19 | 12:00 - 3:00 pm
ABOUT THIS COURSE:
IP management sometimes feels a little like walking around in the dark surrounded by any number of known & unknown dangers. In this session we will explore how you can leverage an IP landscape study (generated by scientists and not software), much like night vision goggles, to assess IP dangers and business opportunities.
By analyzing the landscape from an IP and a technology perspective, you can highlight your company’s strategic positioning at a product, technology, product attribute, and manufacturing level. Join your colleagues to discuss:
- How do you facilitate effective IP communication across in-house legal, business development, senior management and your R&D team leaders?
- What is the threat from your competitors? What is the quality of their patent portfolio and how are they leveraging it?
- How strong is your portfolio in a particular area and how can your continue to maintain a strong position?
- Are there new entrants and what are your partnership and M&A opportunities?
- Can you forecast where the industry is going?
Case studies will presented included those from recent Patent Watch articles in Nature Reviews Drug Discovery written by the presenters covering CGRP treatments for migraines, microbiome modulating therapeutics, and nanoparticle drug delivery.
INSTRUCTORS:
David Berry, M.D., Ph.D., General Partner, Flagship Ventures
David Berry joined Flagship in 2005 where he focuses on innovating, entrepreneuring, and investing in new ventures in life sciences and sustainability. He is a founder of Flagship portfolio companies Joule Unlimited, Eleven Biotherapeutics (NASDAQ: EBIO), Seres Therapeutics (NASDAQ: MCRB), Pronutria Biosciences, LS9 (acquired by Renewable Energy Group) and Symbiota. David has served as founding CEO of Joule, Pronutria and Seres. He currently serves on the boards of Eleven, Pronutria and Avedro. He was previously a Board member of CGI Pharmaceuticals (acquired by Gilead), Joule, Seres and Symbiota. Prior to Flagship, David received an MD from Harvard Medical School and a PhD from the MIT Biological Engineering Division, working in the laboratories of Professors Ram Sasisekharan and Bob Langer, completing the dual degree in just over 5 years. David currently serves on the Leadership Council of the United Nations Sustainable Development Solutions Network. He is currently on the Boards of the Hackley School and the Juventas New Music Ensemble, and has served on the MIT Corporation, its Board of Trustees as well as the Boston Philharmonic Orchestra. David was elected a 2014 Young Global Leader by the World Economic Forum. Previously, David was named the Innovator of the Year by Technology Review, and received the prestigious Lemelson-MIT Student Prize for invention and innovation. He was also selected by the US State Department as 1 of 12 Innovators Helping to Reshape Reality.
Ananda Chakrabarty, Ph.D., Department of Microbiology & Immunology, University of Illinois College of Medicine
Ananda M Chakrabarty Ph.D. is currently a Distinguished University Professor in the Department of Microbiology and Immunology in the University of Illinois, Chicago College of Medicine. He is most notable for his work in directed evolution and his role in developing a genetically engineered organism using plasmid transfer while working at General electric (GE), the patent for which led to landmark Supreme Court case, Diamond v. Chakrabarty. He currently serves as an advisor to judges, governments, and the UN as one of the founding members of a UNIDO Committee that proposed the establishment of the International Center for Genetic Engineering and Biotechnology (ICGEB) and is a member of its Council of Scientific Advisors. He also served as a member of the Board on Biology of the National Academy of Science and Committee on Biotechnology of the National research Council (USA). Prof. Chakrabarty received his Ph.D. from the University of Calcutta, Kolkata, West Bengal.
Anu Daniel, Ph.D., Licensing Manager, Innovation, Partners Healthcare
Anu is responsible for managing intellectual property, developing commercialization strategies and licensing technologies for Endocrinology, the Diabetes Clinical Center, Gastroenterology and Pediatrics at MGH and Newborn Medicine at BWH. Piror to joining Innovation, Anu worked as a Scientist II in the Infectious Disease Department at Cubist Pharmaceuticals in Lexington, MA. Anu received his MSc from the Indian Agricultural Research Institute, New Delhi, India and earned his Ph.D. from the University of Georgia. He conducted his post-doctoral work at the University of Maryland School of Medicine and Rockefeller University.
Drew Lowery, Ph.D., Director of Life Sciences and Group Leader, Biotechnology Pharmaceuticals Group, Global Prior Art, Inc.
Dr. Lowery is the Director of Life Sciences and Group Leader of the Biotechnology & Pharmaceuticals Group, who has worked on and directed projects covering satiety hormones, modified antibodies and high-throughput assays, among others. Dr. Lowery’s additional areas of specialization include: biological signaling networks, therapeutic proteins and oncology. Dr. Lowery received a B.S. with high honors in Biochemistry and Molecular Biology from Penn State University and a Ph.D. in Biochemistry from the Massachusetts Institute of Technology. His graduate work at MIT focused on intracellular signaling networks, particularly phosphorylation-dependent signaling networks involved in cell-cycle control. Dr. Lowery has published numerous scientific articles in top tier journals, including Science and Nature along with two Patent Watch articles in Nature Reviews Drug Discovery.
Amy Mendel, J.D., SVP, Intellectual Property, Evelo Biosciences
Amy Mendel has been a patent attorney with over 13 years of intellectual property law experience focusing on patent prosecution, diligence, litigation and licensing. Experience with protecting small molecules, biologics and biomarkers as well as using intellectual property and FDA regulations to maximize exclusive protection for drugs. She understands business, scientific and financial considerations and uses intellectual property as a strategic tool to accomplish business objectives.
Daniel Neuman, Ph.D., Group Leader, Chemistry & Materials, Global Prior Art, Inc.
Dr. Neuman has directed numerous FTO, acquisition due diligence, prior art, and IP landscape analysis projects for clients in the Pharmaceutical, Chemical and Biotechnology industries. Dr. Neuman’s expertise spans organometallics, spectroscopy, semiconductors, inorganic materials, sol-gel based sensors, polymer science, pharmaceutical formulations, drug delivery platforms, nanomaterials, and photo-activated materials. Dr. Neuman received a B.A. in Chemistry, cum laude, from Boston University where his research focused on the development of transition metal clusters for hydrocarbon activation. While obtaining his Ph.D. in Chemistry from the University of California, Santa Barbara, Dr. Neuman’s research involved the design of nanoparticle (Quantum Dot) -based materials for sensor and drug activation technologies. As a postdoctoral fellow in the Harvard Medical School at Massachusetts General Hospital, Dr. Neuman led a multi-center research project directed at translating nanoparticle platforms for treatment and imaging of ovarian cancer from bench-to-bedside. While at Harvard Medical School Dr. Neuman was awarded the Ruth L. Kirschstein NRSA Postdoctoral Fellowship by the National Institute of Health. He has also authored a number of publications in top tier chemical journals.
<<Back to Short Courses